Akoya Biosciences (AKYA) Expected to Announce Quarterly Earnings on Monday

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) is anticipated to announce its earnings results after the market closes on Monday, March 31st. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $21.34 million for the quarter.

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02). Akoya Biosciences had a negative net margin of 66.77% and a negative return on equity of 162.99%. The company had revenue of $21.34 million for the quarter, compared to analyst estimates of $21.34 million. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Akoya Biosciences Trading Up 2.8 %

Shares of AKYA traded up $0.04 during trading hours on Thursday, hitting $1.49. 104,565 shares of the stock traded hands, compared to its average volume of 345,756. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62. The firm has a market capitalization of $74.23 million, a PE ratio of -1.26 and a beta of 1.32. The business has a fifty day moving average of $2.17 and a 200-day moving average of $2.49. Akoya Biosciences has a 1-year low of $1.39 and a 1-year high of $4.89.

Remove Ads

Analyst Ratings Changes

AKYA has been the topic of a number of research analyst reports. Canaccord Genuity Group lowered Akoya Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Stephens reaffirmed an "equal weight" rating and set a $1.80 price target (down from $3.50) on shares of Akoya Biosciences in a research report on Tuesday. Finally, Piper Sandler cut shares of Akoya Biosciences from an "overweight" rating to a "neutral" rating and set a $2.40 price objective for the company. in a research report on Wednesday, March 5th. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat, Akoya Biosciences has a consensus rating of "Hold" and an average target price of $3.62.

Institutional Investors Weigh In On Akoya Biosciences

An institutional investor recently raised its position in Akoya Biosciences stock. Bank of America Corp DE increased its holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) by 39.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,092 shares of the company's stock after purchasing an additional 8,258 shares during the quarter. Bank of America Corp DE owned 0.06% of Akoya Biosciences worth $67,000 as of its most recent filing with the Securities & Exchange Commission. 79.42% of the stock is currently owned by institutional investors and hedge funds.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.